slc25a25a Antibody

What is SLC25A25 and what experimental approaches should be used to study its functions?

SLC25A25 (Solute Carrier Family 25 Member 25) is a calcium-dependent mitochondrial solute carrier that functions as an ATP-Mg/Pi exchanger, mediating the transport of Mg-ATP in exchange for phosphate across the inner mitochondrial membrane . This transport mechanism catalyzes the net uptake or efflux of adenine nucleotides into or from the mitochondria, allowing the cell to adapt to changing energetic demands . To effectively study SLC25A25 function, researchers should employ multiple complementary approaches. Mitochondrial isolation followed by reconstitution of the purified protein into liposomes can enable direct measurement of transport activity. Genetic manipulation approaches, such as those used to create the floxed Slc25a25 allele in C57BL/6J mice, provide valuable in vivo models for functional studies . Additionally, real-time metabolic flux analysis using platforms such as Seahorse XF analyzers can help quantify how SLC25A25 alterations affect cellular bioenergetics.

How should researchers approach the detection of different SLC25A25 isoforms?

Multiple isoforms of SLC25A25 have been identified, including splice variants like SCaMC-2b which lacks exon 6 . When designing experiments to distinguish between these isoforms, researchers should carefully select primers and probes that target specific regions. For human studies, probes designed from sequences in the C-terminal region can detect all four isoforms of human SLC25A25 (hSCaMC-2a to 2d) . For protein detection, researchers should consider using antibodies targeting different epitopes. Antibodies against the N-terminal region (AA 63-93) will recognize different fragments compared to those targeting other regions like AA 2-110 . Western blotting with appropriate controls and comparison of band patterns at expected molecular weights (the calculated molecular weight is 53 kDa, though observed weights of 50 kDa and 100 kDa have been reported) can help identify specific isoforms . Complementary techniques such as mass spectrometry can provide additional validation of isoform-specific detection.

What are the recommended protocols for SLC25A25 antibody sample preparation?

Optimal sample preparation for SLC25A25 antibody applications begins with proper tissue or cell lysis. Since SLC25A25 is a mitochondrial membrane protein, standard RIPA buffer supplemented with protease inhibitors is recommended for Western blot applications. For immunohistochemistry, antigen retrieval is critical - suggested methods include TE buffer at pH 9.0 or alternatively citrate buffer at pH 6.0 . When working with frozen samples, researchers should avoid repeated freeze-thaw cycles as this can degrade mitochondrial membrane proteins. For the antibody itself, proper reconstitution is essential - for instance, the OSS00282W antibody should be reconstituted in 100 μL of sterile water followed by centrifugation to remove any insoluble material . Researchers should verify protein concentration using methods like BCA assay and standardize loading amounts (typically 20-50 μg total protein per lane for Western blots) to ensure consistent results across experiments.

What criteria should guide selection of SLC25A25 antibodies for specific applications?

Selection of appropriate SLC25A25 antibodies requires consideration of multiple factors specific to the intended application. For Western blotting, both polyclonal (such as ABIN7119274) and monoclonal (like 4D8 clone) antibodies have been validated, with recommended dilutions typically between 1:500-1:1000 . For immunohistochemistry on paraffin-embedded sections, polyclonal antibodies with proven reactivity in your species of interest are preferable, with recommended dilutions of 1:20-1:200 . When selecting antibodies for specific species, verify the cross-reactivity information - some antibodies show reactivity only with human samples, while others (like ABIN7119274) are validated for human, rat, and mouse samples . Consider also the epitope - antibodies targeting the N-terminal region (AA 63-93) may provide different results compared to those recognizing other regions . For specialized applications like immunofluorescence, select antibodies specifically validated for that purpose, such as ab237051, which has been successfully used at 1:100 dilution in ICC/IF experiments with U-251 MG human brain glioma cells .

What validation steps are essential to confirm SLC25A25 antibody specificity?

Comprehensive validation of SLC25A25 antibodies should include multiple complementary approaches. First, positive and negative control samples are critical - RAW 264.7 cells have been identified as positive controls for Western blotting . For negative controls, consider using tissues from SLC25A25 knockout mice (generated using approaches like the floxed Slc25a25 allele with EIIa-Cre recombination) . Peptide competition assays, where the antibody is pre-incubated with its immunizing peptide, can verify specific binding. For instance, with antibodies raised against synthetic peptides, such as those between amino acids 63-93 from the N-terminal region , pre-incubation with the immunizing peptide should abolish specific signals. Additionally, verify consistency of detected molecular weight (expected around 53 kDa, though observed at 50 kDa and 100 kDa in some samples) . For polyclonal antibodies, batch-to-batch variation should be assessed, particularly with antibodies purified through protein A columns followed by peptide affinity purification . Finally, orthogonal validation using techniques like mass spectrometry or RNA interference can provide definitive confirmation of antibody specificity.

How can researchers troubleshoot inconsistent results with SLC25A25 antibodies?

When encountering variable results with SLC25A25 antibodies, a systematic troubleshooting approach is necessary. First, examine antibody storage conditions - most SLC25A25 antibodies should be stored at -20°C with aliquoting recommended for antibodies provided in PBS with 0.02% sodium azide and 50% glycerol (pH 7.3) . Next, optimize protein extraction methods, ensuring complete solubilization of mitochondrial membrane proteins using appropriate detergents. For Western blotting applications showing weak or absent signals, consider adjusting antibody concentration (trying a range around the recommended 1:500-1:1000 dilution) , extending incubation times, or using more sensitive detection methods. For IHC applications, compare different antigen retrieval methods - both TE buffer (pH 9.0) and citrate buffer (pH 6.0) have been recommended for SLC25A25 antibodies . High background issues may be addressed by increasing blocking time or adjusting blocking buffer composition. If these approaches fail, consider testing alternative antibodies targeting different epitopes - the conformation-dependent accessibility of epitopes can vary between applications, particularly for transmembrane proteins like SLC25A25. Finally, verify sample quality, as degraded protein often results in inconsistent antibody binding.

What are the optimized protocols for detecting SLC25A25 via Western blotting?

For optimal Western blot detection of SLC25A25, researchers should use specialized protocols that account for its mitochondrial membrane localization. Begin with sample preparation using RIPA buffer supplemented with protease inhibitors, followed by sonication to ensure efficient extraction of membrane proteins. For gel electrophoresis, 10-12% SDS-PAGE gels are suitable for resolving SLC25A25 (calculated MW: 53 kDa, observed: 50-100 kDa) . After transfer to PVDF membrane (preferred over nitrocellulose for hydrophobic proteins), block with 5% non-fat milk in TBST for 1 hour at room temperature. For primary antibody incubation, use a 1:500-1:1000 dilution of anti-SLC25A25 antibody (such as 21568-1-AP) in blocking buffer overnight at 4°C . Following three 10-minute washes with TBST, incubate with appropriate HRP-conjugated secondary antibody at 1:5000 dilution for 1 hour at room temperature. After additional washing steps, develop using enhanced chemiluminescence. RAW 264.7 cells serve as positive controls for validation . When analyzing results, note that SLC25A25 may appear at different molecular weights due to post-translational modifications or oligomerization, which explains the observation of both 50 kDa and 100 kDa bands in some experiments.

How should immunohistochemistry experiments be designed for SLC25A25 detection?

Effective immunohistochemical detection of SLC25A25 requires careful consideration of tissue preparation and staining protocols. Begin with appropriate fixation - 10% neutral buffered formalin for 24-48 hours is recommended for most tissues. After embedding in paraffin and sectioning (4-6 μm thickness), perform antigen retrieval using TE buffer at pH 9.0, though citrate buffer at pH 6.0 may also be effective for certain antibodies . For blocking, use 10% normal serum from the species of the secondary antibody in PBS with 0.1% Triton X-100 for 1 hour at room temperature. Apply primary SLC25A25 antibody at dilutions ranging from 1:20-1:200 depending on the specific antibody and tissue . For instance, human liver tissue has been successfully used as a positive control for IHC applications . Incubate overnight at 4°C in a humidified chamber. After washing, apply appropriate biotinylated secondary antibody followed by streptavidin-HRP, then develop with DAB substrate. Counterstain with hematoxylin for nuclear visualization. To validate specificity, include appropriate controls: primary antibody omission, isotype control, and ideally, tissue from SLC25A25 knockout models. When interpreting results, expect primarily cytoplasmic/mitochondrial staining patterns with potential intensity variations corresponding to the known differential expression of SLC25A25 across tissues.

What approaches should be used to study SLC25A25 interactions with other proteins?

Investigating SLC25A25's protein interactions requires multiple complementary techniques due to its mitochondrial membrane localization. Co-immunoprecipitation (Co-IP) represents a foundational approach, using validated SLC25A25 antibodies such as the polyclonal antibody targeting AA 1-189 or monoclonal antibody 4D8 . For successful Co-IP, mild detergents like digitonin (0.5-1%) or CHAPS (0.5-1%) better preserve membrane protein complexes compared to stronger detergents like Triton X-100. Proximity ligation assay (PLA) offers an alternative for detecting protein interactions in situ within cells or tissues, particularly valuable for membrane proteins. For identification of novel interaction partners, BioID or APEX2 proximity labeling combined with mass spectrometry is recommended, as these techniques can capture transient or weak interactions that may be lost during traditional pull-down methods. To validate functional relevance of identified interactions, researchers should employ techniques like Förster Resonance Energy Transfer (FRET) or Bimolecular Fluorescence Complementation (BiFC) in living cells. Finally, genetic approaches using the available mouse models with floxed Slc25a25 alleles can provide in vivo validation of identified interactions through comparative proteomics of wild-type versus knockout tissues.

How should researchers investigate the role of SLC25A25 in metabolic regulation?

Investigating SLC25A25's role in metabolism requires a multi-faceted approach leveraging the protein's function as an ATP-Mg/Pi exchanger. Begin with metabolic flux analysis using platforms like Seahorse XF analyzers to measure real-time changes in oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in cells with modulated SLC25A25 expression. For in vivo metabolic studies, the established mouse model with Slc25a25 gene deletion provides a valuable tool, as these mice demonstrate reduced metabolic efficiency, enhanced resistance to diet-induced obesity, and impaired exercise capacity . To explore the mechanistic basis of these phenotypes, researchers should employ targeted metabolomics focusing on adenine nucleotide pools (ATP, ADP, AMP) and related metabolites in mitochondrial and cytosolic fractions. 13C-labeled substrate tracing can further elucidate how SLC25A25 affects specific metabolic pathways. Additionally, calcium imaging techniques are essential, as SLC25A25 is calcium-dependent , allowing investigation of how calcium fluctuations influence its activity and subsequent metabolic outcomes. Finally, tissue-specific conditional knockout models using the floxed Slc25a25 allele crossed with tissue-specific Cre recombinase lines can help delineate the contribution of SLC25A25 to metabolic regulation in specific tissues like liver, skeletal muscle, or adipose tissue.

What methods are most effective for studying SLC25A25-AS1 in cancer research?

Investigating SLC25A25-AS1 (antisense RNA 1) in cancer research requires specialized approaches that differ from those used for the protein-coding gene. RNA interference techniques using siRNAs (si-SLC25A25-AS1) have been successfully employed to silence SLC25A25-AS1 expression in cancer cells like A549 and SK-MES-1 . When designing such experiments, researchers should include multiple siRNA sequences (e.g., si-SLC25A25-AS1#1 and si-SLC25A25-AS1#2) to control for off-target effects, with validation of knockdown efficiency by RT-qPCR . Functional assays should assess hallmark cancer phenotypes - proliferation (using CCK-8 assay), apoptosis (flow cytometry), and migration/invasion (Transwell assays) . For mechanistic studies investigating the competitive endogenous RNA theory, techniques including subcellular fractionation, bioinformatics analysis, luciferase reporter assays, and RNA immunoprecipitation have proven effective in elucidating the SLC25A25-AS1/miR-195-5p/ITGA2 axis in non-small cell lung cancer . TCGA data analysis offers valuable insights into differential expression across cancer types, with SLC25A25-AS1 showing varying patterns - upregulation in lung cancer (associated with poor prognosis) but apparent tumor-suppressive roles in colorectal cancer . For clinical relevance, Kaplan-Meier survival analysis stratifying patients by SLC25A25-AS1 expression levels provides prognostic information. Finally, in vivo validation using xenograft models with SLC25A25-AS1-silenced cancer cells is essential to confirm in vitro findings.

How can researchers effectively study the evolutionary conservation and functional domains of SLC25A25?

To investigate the evolutionary conservation and functional domains of SLC25A25, researchers should employ comparative genomics and structure-function analyses. Begin with multiple sequence alignment of SLC25A25 orthologs across diverse species - the wide cross-reactivity of certain antibodies with zebrafish, pig, monkey, bat, and chicken samples suggests high conservation . Phylogenetic analysis combined with selective pressure analysis (dN/dS ratios) can identify highly conserved regions likely critical for function. For structure-function studies, researchers should focus on known functional domains - the N-terminal region containing EF-hand calcium-binding motifs and the C-terminal carrier domain with six transmembrane segments typical of mitochondrial carriers. Site-directed mutagenesis targeting key residues in these domains, followed by functional assays measuring transport activity in reconstituted liposomes or mitochondria, can establish structure-function relationships. Particularly informative would be mutations in the calcium-binding EF-hands to determine how calcium regulation impacts transport activity. For expression of recombinant protein, both bacterial systems (as used for antibody generation ) and mammalian expression vectors like pCI-neo (successfully used for mouse Slc25a25 cloning ) are viable options. Additionally, chimeric constructs swapping domains between SLC25A25 and related carriers (other SCaMC family members) can help define domain-specific functions. Finally, comparing the properties of natural splice variants, like the variant lacking exon 6 (corresponding to human SCaMC-2b) , provides insights into the functional contributions of specific protein regions.

What are the recommended approaches for generating and validating SLC25A25 knockout models?

Development of SLC25A25 knockout models requires careful genetic engineering approaches tailored to the research question. The established strategy of generating a floxed Slc25a25 allele by introducing loxP sites flanking critical exons (specifically exons 2 and 3) provides flexibility for both global and conditional knockouts . For CRISPR/Cas9-based approaches, gRNAs should target conserved exons shared across splice variants, with validation of editing efficiency in cell lines before proceeding to animal models. Regardless of the genetic modification approach, comprehensive validation is essential. At the DNA level, genomic PCR can confirm the presence of loxP sites or CRISPR-induced modifications . For mRNA validation, primers designed to detect all splice variants (targeting the C-terminal region) should be used in RT-qPCR assays . At the protein level, Western blotting using antibodies like 21568-1-AP (1:500-1:1000 dilution) can confirm protein depletion, with RAW 264.7 cells serving as positive controls. Phenotypic validation should include metabolic assessments, given the established role of SLC25A25 in metabolic efficiency and exercise capacity . For cell-based models, mitochondrial function assays (oxygen consumption rate, membrane potential) are essential validation steps. Finally, researchers should be aware of potential compensatory upregulation of related family members (other SCaMC proteins) that might partially mask knockout phenotypes.

How should researchers design experiments to investigate SLC25A25 regulation by calcium?

To investigate calcium regulation of SLC25A25, researchers must design experiments that specifically address its calcium-dependent transport activity. Begin with in vitro transport assays using purified recombinant SLC25A25 reconstituted into liposomes, measuring ATP-Mg/Pi exchange rates across a range of calcium concentrations (typically from nanomolar to micromolar). This approach allows quantification of calcium activation constants and transport kinetics. For cellular studies, mitochondrial calcium imaging using fluorescent indicators like Rhod-2 AM combined with simultaneous monitoring of adenine nucleotide transport can establish temporal relationships between calcium fluctuations and SLC25A25 activity. Site-directed mutagenesis targeting the EF-hand calcium-binding motifs in the N-terminal domain, followed by functional assays, can definitively establish which calcium-binding sites are critical for activity regulation. To study calcium regulation in intact cells, researchers can employ calcium ionophores like ionomycin or physiological calcium mobilizing agents (IP3-generating agonists) while monitoring mitochondrial bioenergetics. Additionally, confocal microscopy using fluorescently-tagged SLC25A25 can determine whether calcium binding induces conformational changes or alters subcellular localization. Finally, proximity labeling techniques like BioID can identify calcium-dependent changes in SLC25A25's interaction partners, potentially revealing additional regulatory mechanisms beyond direct calcium binding.

What experimental design is recommended for investigating tissue-specific SLC25A25 expression patterns?

A comprehensive investigation of tissue-specific SLC25A25 expression requires a multi-level approach examining both mRNA and protein expression across diverse tissues. For mRNA analysis, quantitative RT-PCR using primers designed to detect all four human isoforms (hSCaMC-2a to 2d) by targeting the C-terminal region provides the most complete expression profile . RNA sequencing offers additional advantages by detecting differential splice variant expression across tissues. For protein-level analysis, Western blotting using validated antibodies like 21568-1-AP (1:500-1:1000 dilution) allows quantitative comparison across tissue lysates. Immunohistochemistry provides complementary spatial information, with human liver tissue serving as a positive control and recommended antibody dilutions of 1:20-1:200 . For higher resolution subcellular localization, immunofluorescence microscopy with mitochondrial co-markers (like MitoTracker or TOM20) confirms the expected mitochondrial localization pattern. To investigate developmental and physiological regulation, researchers should analyze tissues under different conditions (feeding/fasting, exercise/rest, developmental stages) using consistent methodology. Finally, analysis of publicly available transcriptomic datasets (like those in The Cancer Genome Atlas) can provide additional insights into SLC25A25 expression patterns across both normal and pathological tissues , though such findings should be validated using the techniques described above in representative samples.